To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.
Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.
The Quirem team will attend ECIO in Nice from April 26-29 2020.
SIRT in three steps
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:
News and events
Radiology of the Future revolves around smart and fast image processing. Achieving this requires research and entrepreneurship. This is the reason that Thirona, Quirem, and Radboud university medical center work together in the Radiology of
29 January 2020 – LEIPZIG On Wednesday 29th of January 2020 a QuiremSpheres® live case was performed to treat a patient suffering from intrahepatic cholangiocellular carcinoma in the left liver lobe. The procedure – which
Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of Smits et al. on the superior predictive value of 166Ho-Scout
What our customers say